Filing Analysis
Treace Medical Concepts, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2026. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- The filing was made on August 7, 2026.
- It pertains to financial results for the quarter ended June 30, 2026.
- A press release containing the financial results was issued as Exhibit 99.1.
Treace Medical Concepts, Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected three Class II directors, approved executive compensation on an advisory basis, and ratified the appointment of Grant Thornton LLP as the independent auditor for fiscal year 2026.
📋 Key Facts
- The Annual Meeting of Stockholders was held on May 19, 2026.
- Three Class II directors (Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan) were elected to serve three-year terms expiring in 2029.
- Executive compensation was approved on an advisory, non-binding basis with 32,785,505 votes 'For' and 1,724,383 votes 'Against'.
- The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 47,885,305 votes 'For'.
Treace Medical Concepts, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing was made on May 8, 2026, to report financial results for the quarter ended March 31, 2026.
- The company utilized Item 2.02 (Results of Operations and Financial Condition) for the disclosure.
- The press release was furnished as Exhibit 99.1.
- The report was signed by Mark L. Hair, Chief Financial Officer.
Treace Medical Concepts announced the departure of Chief Commercial Officer Gaetano M. Guglielmino and the subsequent elimination of the CCO role. Simultaneously, the company provided a positive preliminary Q1 2026 financial update and raised the lower end of its full-year revenue guidance.
🚩 Red Flags
- Elimination of the Chief Commercial Officer position, which may indicate aggressive cost-cutting or a shift in commercial strategy.
- Company noted 'headwinds from demand driven product and price mix shift' within the bunion portfolio.
📋 Key Facts
- Chief Commercial Officer Gaetano M. Guglielmino departed effective April 8, 2026.
- The Company will not fill the CCO role; the Senior Vice President of Sales will now report directly to CEO John T. Treace.
- Mr. Guglielmino will serve as a consultant through January 31, 2027, receiving a monthly fee of $36,666.67.
- Preliminary Q1 2026 revenue is expected to be $47.0 million to $47.2 million.
- Cash and marketable securities increased by $3.5 million during Q1 to approximately $51.9 million.
- Full-year 2026 revenue guidance was updated to $202 million - $212 million, up from the previous $200 million - $212 million range.
Treace Medical Concepts, Inc. reported its financial results for the fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to this filing.
📋 Key Facts
- The report was filed on February 27, 2026, regarding the fiscal year ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- Mark L. Hair, Chief Financial Officer, signed the report.
- The press release (Exhibit 99.1) is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Treace Medical Concepts, Inc. issued an 8-K to announce preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. The company also released an investor presentation ahead of the J.P. Morgan Healthcare Conference.
📋 Key Facts
- Released preliminary unaudited financial results for Q4 and FY 2025 on January 13, 2026.
- Published a new investor presentation via Exhibit 99.2.
- Scheduled to participate in the J.P. Morgan Healthcare Conference on January 14, 2026.
Treace Medical Concepts entered into a new $125 million term loan and a $30 million revolving credit facility with SLR Investment Corp. to refinance existing debt from MidCap Financial Trust.
🚩 Red Flags
- Significant prepayment/exit fees ($2.3M) incurred to refinance debt.
- Debt is secured by substantially all company assets, including IP.
- Restrictive covenants: Minimum liquidity requirement (cash must exceed 60% of term loans outstanding) or revenue covenants if liquidity fails.
📋 Key Facts
- Entered into a 60-month Term Loan Agreement for up to $125 million; $60 million drawn at closing in four tranches.
- Established a 60-month Revolving Loan Agreement with a $30 million capacity (expandable to $50 million).
- Term loan interest rate: 1-Month SOFR + 5.05% (floor of 3.00%).
- Revolving loan interest rate: 3-Month SOFR + 4.00% (floor of 3.00%).
- Loans are secured by substantially all company assets, including intellectual property.
- Company paid $2.3 million in prepayment and exit fees to terminate existing MidCap Loan Agreements.
Treace Medical Concepts, Inc. announced the retirement of Richard W. Mott from the Board of Directors and his roles as Lead Independent Director and committee member. The company also reduced its total Board size from eight to seven members.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Richard W. Mott retired from the Board of Directors on November 3, 2025.
- Mr. Mott served as Lead Independent Director and was a member of the Compensation Committee and Nominating and Corporate Governance Committee.
- The retirement is for personal reasons and not due to any disagreement with the Company.
- The Board size was reduced from eight members to seven effective November 5, 2025.
- The company issued quarterly financial results for the period ended September 30, 2025 via Item 2.02.
Treace Medical Concepts, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes Exhibit 99.1 containing the press release of financial results
- Signed by Mark L. Hair, Chief Financial Officer
Treace Medical Concepts, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on May 20, 2025. The meeting included elections for directors, an advisory vote on executive compensation, and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on May 20, 2025.
- Lawrence W. Hamilton was elected to the Board of Directors (40,663,919 votes for).
- Deepti Jain was elected to the Board of Directors (34,754,249 votes for).
- Stockholders approved executive compensation on an advisory basis (39,922,580 votes for).
- Grant Thornton LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Treace Medical Concepts, Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the quarter ended March 31, 2025.
📋 Key Facts
- The filing relates to financial results for the quarter ending March 31, 2025.
- A press release was issued on May 8, 2025, as Exhibit 99.1.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
James T. Treace has announced his intention to retire from the Board of Directors at the 2025 annual meeting. Concurrently, CEO John T. Treace will assume the role of Chairman of the Board upon James's departure.
🚩 Red Flags
- Related-party transition: The departing director is a relative (uncle) of the CEO, and the CEO is stepping into the vacated seat/role structure.
- Reduction in Board size from 9 to 8 directors.
📋 Key Facts
- James T. Treace notified the Board on April 2, 2025, of his intent to retire at the expiration of his term at the 2025 Annual Meeting.
- John T. Treace (CEO) will be appointed Chairman of the Board effective upon James's retirement.
- James T. Treace is the uncle of CEO John T. Treace.
- The Board size will decrease from nine directors to eight following the departure.
- No change in compensation for John T. Treace is expected due to the Chairman appointment.
Treace Medical Concepts, Inc. filed an 8-K to announce the issuance of a press release regarding its financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- The filing reports on Item 2.02 (Results of Operations and Financial Condition).
- Financial results pertain to the year ended December 31, 2024.
- A press release was issued on February 27, 2025, as Exhibit 99.1.
Treace Medical Concepts, Inc. issued an 8-K to announce preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2024. The company also released an investor presentation in preparation for the J.P. Morgan Healthcare Conference.
📋 Key Facts
- Released preliminary unaudited financial results for Q4 and FY 2024 on January 13, 2025.
- Published a new investor presentation via Exhibit 99.2.
- Scheduled to present at the J.P. Morgan Healthcare Conference on January 14, 2025.
Treace Medical Concepts, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended September 30, 2024.
📋 Key Facts
- The filing was made on November 5, 2024.
- The company issued a press release regarding financial results for the quarter ended September 30, 2024 (Exhibit 99.1).
- The information provided under Item 2.02 is furnished rather than filed, limiting liability under Section 18 of the Exchange Act.
Treace Medical Concepts announced a patent infringement and unfair competition lawsuit against Stryker Corporation and Wright Medical Technology, Inc. The company also reaffirmed its 2024 Adjusted EBITDA guidance and expects to reach Adjusted EBITDA breakeven in 2025.
🚩 Red Flags
- Litigation risk: Patent infringement lawsuits can be costly and time-consuming, potentially impacting market share or requiring significant legal expenditures.
📋 Key Facts
- Filed a lawsuit against Stryker Corporation and subsidiary Wright Medical Technology, Inc. alleging patent infringement and unfair competition on October 14, 2024.
- Reaffirmed previously stated guidance for Adjusted EBITDA for the full year 2024.
- Management expects to reach Adjusted EBITDA breakeven in 2025.
Treace Medical Concepts, Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard disclosure of quarterly earnings results (Item 2.02).
- The reporting period covered is the quarter ended June 30, 2024.
- The company issued a press release as Exhibit 99.1 to accompany this report.
Treace Medical Concepts, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 21, 2024. The meeting included elections for directors, advisory votes on executive compensation frequency, and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- The 2024 Annual Meeting was held on May 21, 2024.
- Three nominees (John K. Bakewell, Richard W. Mott, and John T. Trece) were elected to the Board of Directors for three-year terms expiring in 2027.
- Stockholders approved executive compensation on a non-binding advisory basis.
- Stockholders voted to hold future 'Say-on-Pay' advisory votes every 1 year.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Treace Medical Concepts, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2024 and provided an updated investor presentation.
📋 Key Facts
- Company issued a press release regarding financial results for the quarter ended March 31, 2024 (Exhibit 99.1).
- Company released an investor presentation via its website (Exhibit 99.2).
- The filing was signed by CFO Mark L. Hair on May 7, 2024.
Treace Medical Concepts, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023, and provided an updated investor presentation.
📋 Key Facts
- Report date: February 27, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a press release regarding financial results (Exhibit 99.1)
- The filing includes an investor presentation (Exhibit 99.2)
Treace Medical Concepts, Inc. filed an 8-K to furnish an investor presentation released in conjunction with the J.P. Morgan Healthcare Conference on January 9, 2024.
📋 Key Facts
- The company posted an updated investor presentation via its website.
- Management presented at the J.P. Morgan Healthcare Conference on January 9, 2024.
- Information furnished under Item 7.01 is considered 'furnished' rather than 'filed', meaning it is not subject to certain liabilities under Section 18 of the Exchange Act.
Treace Medical Concepts, Inc. issued a press release regarding preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing pertains to preliminary unaudited financial results for the period ending December 31, 2023.
- Results were released via press release on January 8, 2024.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.